Literature DB >> 17237290

Pharmacologic inhibition of CDC25 phosphatases impairs interphase microtubule dynamics and mitotic spindle assembly.

Martine Cazales1, Rose Boutros, Marie-Christine Brezak, Sophie Chaumeron, Grégoire Prevost, Bernard Ducommun.   

Abstract

The CDC25 cell cycle regulators are promising targets for new pharmacologic approaches in cancer therapy. Inhibitory compounds such as BN82685 have proven to be effective in specifically targeting CDC25 in cultured cells and in inhibiting tumor cell growth. Here, we report that BN82685 impairs microtubule dynamic instability and alters microtubule organization and assembly at the centrosome in interphase cells. Treatment of mitotic cells with BN82685 delays mitotic spindle assembly, chromosome capture, and metaphase plate formation. Furthermore, we show that combining low concentrations of both BN82685 and paclitaxel inhibits the proliferation of HT29 human colon cancer cells. Our results show a role for CDC25 phosphatases in regulating microtubule dynamics throughout the cell cycle and suggest that combinations of CDC25 inhibitors with microtubule-targeting agents may be of therapeutic value.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17237290     DOI: 10.1158/1535-7163.MCT-06-0299

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  6 in total

Review 1.  New combination therapies with cell-cycle agents.

Authors:  Gagan Deep; Rajesh Agarwal
Journal:  Curr Opin Investig Drugs       Date:  2008-06

Review 2.  Biology of the mRNA Splicing Machinery and Its Dysregulation in Cancer Providing Therapeutic Opportunities.

Authors:  Maxime Blijlevens; Jing Li; Victor W van Beusechem
Journal:  Int J Mol Sci       Date:  2021-05-12       Impact factor: 5.923

3.  Design and synthesis of substituted (1-(benzyl)-1H-1,2,3-triazol-4-yl)(piperazin-1-yl)methanone conjugates: study on their apoptosis inducing ability and tubulin polymerization inhibition.

Authors:  Kesari Lakshmi Manasa; Sowjanya Thatikonda; Dilep Kumar Sigalapalli; Sowmya Vuppaladadium; Ganthala Parimala Devi; Chandraiah Godugu; Mallika Alvala; Narayana Nagesh; Bathini Nagendra Babu
Journal:  RSC Med Chem       Date:  2020-09-08

4.  Cdc25B dual-specificity phosphatase inhibitors identified in a high-throughput screen of the NIH compound library.

Authors:  Paul A Johnston; Caleb A Foster; Marni Brisson Tierno; Tong Ying Shun; Sunita N Shinde; William D Paquette; Kay M Brummond; Peter Wipf; John S Lazo
Journal:  Assay Drug Dev Technol       Date:  2009-06       Impact factor: 1.738

5.  Reversal effects of Raloxifene on paclitaxel resistance in 2 MDR breast cancer cells.

Authors:  Liang Xu; Jingyu Lei; Donghai Jiang; Lin Zhou; Shu Wang; Weimin Fan
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

6.  Bioactivities of simplified adociaquinone B and naphthoquinone derivatives against Cdc25B, MKP-1, and MKP-3 phosphatases.

Authors:  Shugeng Cao; Brian T Murphy; Caleb Foster; John S Lazo; David G I Kingston
Journal:  Bioorg Med Chem       Date:  2008-11-08       Impact factor: 3.641

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.